Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
AGMB-447 by AgomAb Therapeutics for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
AGMB-447 is under clinical development by AgomAb Therapeutics and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData,...